Weekly Medical Device News Roundup (April 13–19, 2026): Innovations, Approvals, and Funding Highlights

Recently, the headquarters of China's leading flexible rehabilitation robot company in the brain-computer interface field, AMYGDALA NEURO, began operations in Liangxi District. The company has established an integrated "research and development - manufacturing - service" system, injecting momentum into the intelligent rehabilitation industry in the Yangtze River Delta. Focusing on hand function flexible rehabilitation robots, the company collaborates with top-tier teams. Its products have been approved for a Class III medical device registration certificate for brain-computer interfaces and have deployed hundreds of devices across multiple regions. The products are included in Wuxi City’s community rental service directory for rehabilitation aids, while simultaneously launching “Internet + home-based rehabilitation” services. On the same day, AMYGDALA NEURO released its brain-computer interface cloud rehabilitation platform, addressing the challenge of “discharge equals loss of management,” by building a “digital bridge” to extend resources from tertiary hospitals to households. Additionally, Liangxi District organized a closed-door symposium where government, enterprises, research institutions, and investors engaged in in-depth discussions, reached consensus, and accelerated the industrial cluster development of brain-computer interfaces.

Recently, Shuimu Jingzhi, a third-party实景化 medical training and achievement transformation platform, has opened in Beijing. The platform collaborates with multiple medical enterprises to address the standardization challenges of grassroots endoscopic technology. For instance, Shuyou Medical empowers practical training with innovative instruments, Bangyun Medical enhances surgical efficiency with knotless barbed sutures, and Huanuo Kang provides high-end equipment to solidify the hardware foundation. The实景实训 model integrates academic standards, practical scenarios, and industrial resources, creating a standardized growth platform for grassroots surgeons and promoting the homogenized development of surgical diagnostic techniques. This platform represents a key innovative practice in the field of medical technology achievement transformation, completing the closed loop of medical innovation achievement transformation. It is reported that the platform will next collaborate with more industry partners to upgrade the training system, promote standardized procedures and innovative instruments to reach the county level, and cultivate grassroots surgical talents.

Recently, Wuhan United Imaging Intelligence Medical Technology Co., Ltd., a company based in Optics Valley, successfully developed a self-innovated endoscopic surgical robot with imaging fusion capabilities. The robot has been applied clinically across multiple departments in several Class A tertiary hospitals in China, including hepatobiliary, urology, gastroenterology, gynecology, and thoracic surgery, showing positive results, and is set to be officially launched within the year. This achievement marks an important breakthrough for United Imaging in the field of high-end medical equipment. In addition, United Imaging has made extensive progress under this system, successfully developing various products such as CT real-time image-guided interventional surgical robots and the Magic Cube hybrid operating room, showcasing its strong innovation capability and deep technological expertise in the medical technology field.

Recently, at the National Brain-Computer Interface Clinical Application and Transformation Conference, the Fengtai-Tiantan Brain-Computer Interface Major Project was announced. Fengtai District and Beijing Tiantan Hospital will jointly build a brain-computer interface innovation industrial park, planning 500,000 square meters of industrial space, and establish a Brain-Computer Interface Clinical Research and Transformation Alliance. The focus will be on building four research centers: the Brain Research Center, Brain Computing Power Center, Brain Health Center, and Brain Rehabilitation Center, which will respectively focus on key technology R&D breakthroughs, providing computing power support, deepening full-cycle brain disease management, and constructing a new paradigm for brain-controlled active rehabilitation. In addition, the two parties will also build a large brain health model and launch an "AI Brain Health Doctor." Fengtai District will collaborate with social capital to establish an industrial fund, construct a "1+N" fund matrix, promote the settlement of enterprises and R&D centers in the park, focus on overcoming cutting-edge technological challenges, and accelerate the clinical application and industrialization process of brain-computer interface technology.

Recently, the "Proof-of-Concept Center" of the NeuroMed Innovation and Translation Alliance (CNIT) has been established at Tongqiao Medical in Zhuhai High-Tech Zone, marking the landing of a national-level industry-university-research collaborative innovation platform in the field of neurovascular intervention in China, strengthening Zhuhai High-Tech Zone's "clinical-research-industry" collaborative innovation system. The establishment of this center is a recognition of Tongqiao Medical’s independent innovation capabilities, which will shorten the transformation cycle of neurovascular interventional devices and accelerate the market entry of innovative achievements. Chairman Zhao Zhong of Tongqiao Medical hopes to deepen cooperation and promote the transformation of results by taking this opportunity; General Manager Li Zheng showcased the company's innovation development process and core technology advantages, with several technologies filling domestic gaps. On the same day, the selection activity for Phase IV of the CNIT Innovation Academy was held, where experts discussed key industry issues.

On April 10, 2026, Revvity and Leader Health Technology officially signed a strategic cooperation agreement. Revvity Vice President Liu Jiang and Leader Health CEO Zhang Feng represented the signing parties, with both core teams in attendance as witnesses. This collaboration focuses on solution innovation and localization exploration, building a full-chain innovative ecosystem around the cell industry chain to enhance supply chain stability and product standardization. During the signing ceremony, both parties held discussions on the local layout of life science instruments and high-quality international development. Zhang Feng stated that Leader Health would leverage Revvity's global resources to optimize the transfer production process and address industry pain points. Liu Jiang noted that Revvity's technology complements Leader Health’s local innovation strengths, which will advance the localization of products. This partnership achieves resource complementarity and mutual benefit, injecting momentum into the high-end and international upgrading of China’s life science instrument and equipment industry, and promoting local scientific achievements to reach a global audience.

On April 12, the Xirun Medical Headquarters Base project began operations in Liangxi District, Wuxi, marking the establishment of an integrated "research and development - manufacturing - service" system, entering a new stage of development, and injecting momentum into Liangxi District's efforts to build a smart rehabilitation hub. Focusing on the field of hand function flexible rehabilitation robots, Xirun Medical collaborates with top-tier teams. Its products enable high-level paraplegic patients to control their fingers through "thought," while its invasive brain-computer interface rehabilitation products have completed dozens of clinical trials and obtained the world’s first Class III medical device registration certificate. The company has simultaneously launched an "Internet + home-based rehabilitation" service and released a brain-computer interface cloud rehabilitation platform, addressing the issue of "loss of management upon discharge" and reducing patient costs. In the future, the company will deepen cooperation using its Liangxi headquarters as a base and promote the extension of rehabilitation services. The establishment of Xirun Medical represents the results of Liangxi District’s efforts in building a brain-computer interface industry ecosystem. On the day of production commencement, a closed-door symposium for ecosystem companies was also held.

Recently, B. Braun Medical from Germany announced the groundbreaking of the third phase project of its Suzhou surgical instruments factory, with a total investment of nearly 100 million yuan, planning to commence operations in 2027. B. Braun Medical Group has a long history and ranks 15th among the top 100 global medical device companies, covering multiple core areas of the medical industry. This increased investment in China aims to front-load the global core surgical instrument production capacity, responding to centralized procurement with localized manufacturing, shortening delivery cycles, reducing costs, and maintaining high-end market barriers. The third phase project focuses on the localized production of high-precision basic surgical instruments. Upon reaching full production, the annual capacity will reach 3 million pieces, adding over 100 million yuan in output value, while integrating the entire production chain digitally through the MES system. Currently, as China's medical device manufacturing undergoes transformation, B. Braun’s practices provide the industry with a replicable model for the localization of high-end foreign devices, deeply integrating German industrial standards with China’s supply chain to enhance the discourse power of "Made in China."

Recently, the State Council Information Office held a regular policy briefing to introduce the "Several Measures on Accelerating the Construction of a Tiered Medical Diagnosis System." First, it encourages grassroots organizations to make good use of pricing policies to provide appropriate services. Grassroots organizations are guided to utilize price item policies effectively, combined with the implementation of project guidelines, encouraging them to take advantage of home visit fees, hospice care fees, family sickbed setup fees, internet follow-up consultation fees, and traditional Chinese medicine rehabilitation services. It also optimizes price management in primary healthcare institutions and implements general treatment fee policies. Second, it supports large hospitals in applying new clinical services and technologies. Third, it continuously optimizes the structure of medical service prices. Since 2021, all provinces have established a dynamic adjustment mechanism for medical service prices. Each region conducts annual price adjustment evaluations, and regions meeting the adjustment criteria can proceed with price adjustments. The adjustment of medical service prices reflects "both increases and decreases," with prices for equipment-heavy procedures such as CT scans and MRIs being reduced.

Recently, the "Guiding Opinions on Promoting the High-Quality Development of the Biomedical Industry in Zhejiang Province (Draft for Soliciting Opinions)" was opened for public comments. It mentioned supporting the R&D of cutting-edge technologies and products. Driven by clinical needs, accelerate the layout in frontier areas such as cell and gene therapy, novel antibody drugs, new small molecule drugs, nucleic acid drugs, radiopharmaceuticals, modern Chinese medicine, medical artificial intelligence, and high-end medical devices, and formulate a key R&D list for innovative drugs and innovative medical devices. Systematically implement application-oriented basic research projects and major provincial science and technology special programs in the biomedical field. Support the construction of biomedicine intellectual property operation centers, and enhance patent navigation analysis and high-value patent fast pre-examination services.

Recently, the Hunan Provincial Medical Security Bureau announced that the National Medical Security Administration's "Guidelines for the Establishment of Medical Service Price Items for Surgical and Treatment Auxiliary Operations (Trial)" has been implemented in Hunan. Previously, surgical robot fees were charged "based on equipment usage," with unclear categories, increasing the burden on patients and making it difficult for medical insurance to intervene. The new guidelines set prices based on the level of robot involvement and clinical value in surgeries: the higher the involvement, the higher the charge coefficient. A new item, "Remote Surgery Auxiliary Operation Fee," has also been established. Hunan has responded to the new regulations by dividing the charges into four categories: navigation-based services are charged at 50% of the main surgery price, with a maximum of 3,600 yuan; participation-based services are charged at 150%, capped at 12,000 yuan and floored at 5,000 yuan; precision execution services are charged at 300%, capped at 26,000 yuan and floored at 16,000 yuan; remote surgery services are charged at 500%, with a maximum of 37,000 yuan.

On April 13, the National Center for ADR Monitoring of Medicines released the "Good Vigilance Practice for Medical Devices (Trial) (Revised Version)" to standardize post-market vigilance activities for medical devices. The GVP comprises 8 chapters and 33 articles, applicable to medical device registrants, record-filers, and domestic responsible persons for imported medical devices in China. It requires them to establish a medical device vigilance system, develop a vigilance plan adapted to product risks, and monitor, identify, evaluate, and control adverse events related to medical devices to reduce uncertainties in harm and risk occurrences, ensuring the safety of relevant personnel. The vigilance system must be integrated into the quality management system, with a focus on eight key aspects including organizational structure setup and management system formulation. The vigilance plan is an important document, covering product scope, vigilance objectives, and other contents. Additionally, the GVP clarifies vigilance data collection, risk control, and other content. Drug regulatory authorities in 17 provinces (regions, municipalities) including Beijing and Hebei will organize the trial implementation.